Phase 2 N=38 Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Nicotine Dependence
Primary: Continuous Four-week Abstinence From Smoking — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=290 Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
Relapsing-Remitting Multiple Sclerosis
Primary: Cumulative Number of Combined Unique Active Lesions — 0.23; 0.02; 3.84; 3.08 lesions
Phase 2 N=168 A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Extensive Stage Small Cell Lung Carcinoma · Recurrent Small Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 4.4; 4.4; 4.6 months — p=0.45
Phase 2 N=55 A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Influenza
Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants
Phase 2 N=22 Doxazosin for Psychostimulant Dependence
Methamphetamine or Cocaine Dependence
Primary: Change in Psychostimulant-positive Urines Over Time — .6; .41; .79; .25 proportion of psychostimulant-pos urines — p=0.05
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 2 N=25 Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Overall Response Rate of GTI-2040 Combined With HiDAC in Refractory or Relapsed AML — 3; 4 participants
Phase 2 N=47 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Phase 2 N=66 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Adenocarcinoma of the Rectum · Mucinous Adenocarcinoma of the Colon · Recurrent Colon Cancer
Primary: Severe Adverse Event (SAE) Rate — 2; 2 participants
Phase 2 N=25 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants
Phase 2 N=22 Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Phase 2 N=5 Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months
Sedation · Pain
Primary: Area Under the Plasma Concentration-time Curve (AUC0-∞) — 4639.17; 14203.544 picogram*hour per millilitre
Phase 2 N=983 A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16 — -0.83; -0.72; -0.66; -0.64 percentage of HbA1c — p=<0.0001
Phase 2 N=60 Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients
Renal Failure
Primary: Evaluation of Steady State Tacrolimus Trough Levels (C24). — 7.00 ng/mL
Phase 2 N=202 Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
HIV Infection · Rotavirus Infection
Primary: Percentage of Participants Developing New Grade >=3 Adverse Events — 1.6; 4.7; 13.5; 12.8 Percentage of participants — p=0.62